How a Melanoma Expert's Final Trial Could Reshape Brain Cancer Treatment

Richard Scolyer, the world's leading melanoma pathologist, died in June 2026 at 59 from glioblastoma. Before his death, he and colleague Georgina Long designed an experimental immunotherapy treatment—adapting insights from their melanoma work—that he received as the first brain cancer patient to try it. The trial continues in the U.S., testing whether immune-based approaches that revolutionized melanoma can break through glioblastoma's resistance.